For the estimated ten million people worldwide living with Parkinson's disease, the central frustration of treatment has long been the same: levodopa works, but not consistently. Motor fluctuations and involuntary movements accumulate over years of therapy, eroding quality of life even as the underlying disease progresses. A comprehensive review now maps precisely how the treatment landscape is shifting to address this core problem.
The review, published in Drugs, catalogs both recently approved agents and pipeline candidates in advanced clinical development. The fundamental challenge—dopamine's short half-life forcing pulsatile receptor stimulation—is being attacked on multiple fronts. Extended-release oral levodopa (IPX203) and inhaled levodopa powder target faster or more sustained plasma levels. Subcutaneous continuous infusion systems, notably foslevodopa/foscarbidopa and ND0612, aim to replicate the smoother dopamine delivery historically achievable only via intrajejunal pump. Apomorphine, a full dopamine agonist with efficacy comparable to levodopa, is gaining traction through subcutaneous and sublingual formulations that expand its practical use. Beyond dopamine substitution, the review also addresses adenosine A2A antagonists, MAO-B inhibitors, and early-stage disease-modifying candidates targeting α-synuclein aggregation and neuroinflammatory pathways.
This synthesis matters because it reflects a genuine philosophical shift: from chasing symptom control with ever-larger levodopa doses toward maintaining steadier drug exposure and, eventually, slowing neuronal loss itself. That said, important caveats apply. Most disease-modifying candidates remain in Phase II, with no agent yet demonstrating unambiguous neuroprotection in a Phase III trial. Continuous infusion therapies carry real-world barriers—device complexity, infection risk, and cost—limiting their reach to advanced cases. For health-conscious adults tracking neurological longevity, the practical implication is that the therapeutic toolkit for Parkinson's is meaningfully expanding, but the window between symptom onset and irreversible motor disability remains the critical interval where future interventions will need to prove their worth.